2020 Korean guidelines for the management of metastatic prostate cancer

키워드

참고문헌 (132)

1. "Levels of evidence (March 2009)" (2009)[URL]
2. Guyatt GH, "GRADE : an emerging consensus on rating quality of evidence and strength of recommendations", BMJ, 336, pp.924~926 (2008)
3. Morris MJ, "Optimizing anticancer therapy in metastatic non-castrateprostate cancer : American Society of Clinical Oncology clinical practice guideline", J Clin Oncol, 36, pp.1521~1539 (2018)
4. "Prostate cancer (Version 2.2019)" (2019)[URL]
5. Cornfford P, "EAU-ESTRO-SIOG guidelines on prostate cancer. Part II : treatment of relapsing, metastatic, and castration-resistant prostate cancer", Eur Urol, 71, pp.630~642 (2017)
6. Parker C, "Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 26(Suppl 5), pp.v69~v77 (2015)
7. Samson DJ, "Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma", Cancer, 95, pp.361~376 (2002)
8. Trachtenberg J, "A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer", J Urol, 167, pp.1670~1674 (2002)
9. Klotz L, "The efficacy and safety of degarelix : a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer", BJU Int, 102, pp.1531~1538 (2008)
10. Gravis G, "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer(GETUG-AFU 15) : a randomised, open-label, phase 3 trial", Lancet Oncol, 14, pp.149~158 (2013)
11. Sweeney CJ, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer", N Engl J Med, 373, pp.737~746 (2015)
12. James ND, "Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer(STAMPEDE) : survival results from an adaptive, multiarm, multistage, platform randomised controlled trial", Lancet, 387, pp.1163~1177 (2016)
13. Kyriakopoulos CE, "Chemohormonal therapy in metastatic hormone-sensitive prostate cancer : long-term survival analysis of the randomized phase III E3805 CHAARTED trial", J Clin Oncol, 36, pp.1080~1087 (2018)
14. Clarke NW, "Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer : long-term survival results from the STAMPEDE trial", Ann Oncol, 30, pp.1992~2003 (2019)
15. Gravis G, "Androgen deprivation therapy(ADT)plus docetaxel versus ADT alone in metastatic non castrate prostate cancer : impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial", Eur Urol, 70, pp.256~262 (2016)
16. Tucci M, "Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer : a systematic review and meta-analysis", Eur Urol, 69, pp.563~573 (2016)
17. Vale CL, "Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer : a systematic review and meta-analyses of aggregate data", Lancet Oncol, 17, pp.243~256 (2016)
18. Attard G, "Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer", BJU Int, 96, pp.1241~1246 (2005)
19. Tran C, "Development of a second-generation antiandrogen for treatment of advanced prostate cancer", Science, 324, pp.787~790 (2009)
20. Clegg NJ, "ARN-509 : a novel antiandrogen for prostate cancer treatment", Cancer Res, 72, pp.1494~1503 (2012)
21. Fizazi K, "Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer", N Engl J Med, 377, pp.352~360 (2017)
22. Fizazi K, "Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer(LATITUDE) : final overall survival analysis of a randomised, double-blind, phase 3 trial", Lancet Oncol, 20, pp.686~700 (2019)
23. James ND, "Abiraterone for prostate cancer not previously treated with hormone therapy", N Engl J Med, 377, pp.338~351 (2017)
24. Hoyle AP, "Abiraterone in"high-"and"low-risk"metastatic hormone-sensitive prostate cancer", Eur Urol, 76, pp.719~728 (2019)
25. Davis ID, "Enzalutamide with standard first-line therapy in metastatic prostate cancer", N Engl J Med, 381, pp.121~131 (2019)
26. Armstrong AJ, "ARCHES : a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer", J Clin Oncol, 37, pp.2974~2986 (2019)
27. Chi KN, "Apalutamide for metastatic, castration-sensitive prostate cancer", N Engl J Med, 381, pp.13~24 (2019)
28. Studer UE, "Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent : European Organisation for Research and Treatment of Cancer(EORTC)Trial 30891", J Clin Oncol, 24, pp.1868~1876 (2006)
29. Kirk D, "Timing and choice of androgen ablation", Prostate Cancer Prostatic Dis, 7, pp.217~222 (2004)
30. Studer UE, "Immediate versus deferred hormonal treatment for patients with prostate cancer who are not suitable for curative local treatment : results of the randomized trial SAKK 08", 88, 2004, pp.22, 4109~4118
31. Scher HI, "Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone : recommendations of the Prostate Cancer Clinical Trials Working Group", J Clin Oncol, 26, pp.1148~1159 (2008)
32. Eisenhauer EA, "New response evaluation criteria in solid tumours : revised RECIST guideline(version 1. 1)", Eur J Cancer, 45, pp.228~247 (2009)
33. Schwartz LH, "RECIST 1. 1. Standardisation and disease-specific adaptations : perspectives from the RECIST Working Group", Eur J Cancer, 62, pp.138~145 (2016)
34. Leone G, "Antiandrogen withdrawal syndrome(AAWS)in the treatment of patients with prostate cancer", Endocr Relat Cancer, 25, pp.R1~R9 (2018)
35. Ryan CJ, "Abiraterone in metastatic prostate cancer without previous chemotherapy", N Engl J Med, 368, pp.138~148 (2013)
36. Basch E, "Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer : patient-reported outcome results of a randomised phase 3 trial", Lancet Oncol, 14, pp.1193~1199 (2013)
37. Beer TM, "Enzalutamide in metastatic prostate cancer before chemotherapy", N Engl J Med, 371, pp.424~433 (2014)
38. de Bono JS, "Abiraterone and increased survival in metastatic prostate cancer", N Engl J Med, 364, pp.1995~2005 (2011)
39. Fizazi K, "Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer : final overall survival analysis of the COU-AA-301randomised, double-blind, placebo-controlled phase 3study", Lancet Oncol, 13, pp.983~992 (2012)
40. Scher HI, "Increased survival with enzalutamide in prostate cancer after chemotherapy", N Engl J Med, 367, pp.1187~1197 (2012)
41. Graff JN, "Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer : results from PREVAIL", Ann Oncol, 27, pp.286~294 (2016)
42. Tannock IF, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer", N Engl J Med, 351, pp.1502~1512 (2004)
43. Berthold DR, "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer : updated survival in the TAX 327 study", J Clin Oncol, 26, pp.242~245 (2008)
44. Kellokumpu-Lehtinen PL, "2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer : a randomised, phase 3 trial", Lancet Oncol, 14, pp.117~124 (2013)
45. de Bono JS, "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment : a randomised open-label trial", Lancet, 376, pp.1147~1154 (2010)
46. Eisenberger M, "Phase III study comparing a reduced dose of cabazitaxel(20 mg", m 2)and the currently approved dose(25 mg, J Clin Oncol, pp.2017, 35[DOI]
47. Oudard S, "Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer : a randomized phase III trial-FIRSTANA", J Clin Oncol, 35, pp.3189~3197 (2017)
48. de Wit R, "Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer", N Engl J Med, 381, pp.2506~2518 (2019)
49. Parker C, "Alpha emitter radium-223 and survival in metastatic prostate cancer", N Engl J Med, 369, pp.213~223 (2013)
50. Smith M, "Addition of radium-223to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases(ERA 223) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 20, pp.408~419 (2019)
51. Mullane SA, "Precision medicine for advanced prostate cancer", Curr Opin Urol, 26, pp.231~239 (2016)
52. Cancer Genome Atlas Research Network, "The molecular taxonomy of primary prostate cancer", Cell, 163, pp.1011~1125 (2015)
53. Castro E, "Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer", J Clin Oncol, 31, pp.1748~1757 (2013)
54. Mateo J, "DNA repair in prostate cancer : biology and clinical implications", Eur Urol, 71, pp.417~425 (2017)
55. Mateo J, "DNA-repair defects and olaparib in metastatic prostate cancer", N Engl J Med, 373, pp.1697~1708 (2015)
56. Mateo J, "Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations(TOPARP-B) : a multicentre, open-label, randomised, phase 2 trial", Lancet Oncol, 21, pp.162~174 (2020)
57. de Bono J, "Olaparib for metastatic castration-resistant prostate cancer", N Engl J Med, 382, pp.2091~2102 (2020)
58. Beer TM, "Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer", J Clin Oncol, 35, pp.40~47 (2017)
59. Hansen AR, "Pembrolizumab for advanced prostate adenocarcinoma : findings of the KEYNOTE-028 study", Ann Oncol, 29, pp.1807~1813 (2018)
60. Antonarakis ES, "Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer : multicohort, open-label phase II KEYNOTE-199 study", J Clin Oncol, 38, pp.395~405 (2020)
61. El-Amm J, "The current landscape of treatment in non-metastatic castration-resistant prostate cancer", Clin Med Insights Oncol, 13, pp.1179554919833927~ (2019)
62. Smith MR, "Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer : exploratory analyses by baseline prostate-specific antigen doubling time", J Clin Oncol, 31, pp.3800~3806 (2013)
63. Smith MR, "Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer", J Clin Oncol, 23, pp.2918~2925 (2005)
64. Smith MR, "Apalutamide treatment and metastasis-free survival in prostate cancer", N Engl J Med, 378, pp.1408~1418 (2018)
65. Hussain M, "Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer", N Engl J Med, 378, pp.2465~2474 (2018)
66. Fizazi K, "Darolutamide in nonmetastatic, castration-resistant prostate cancer", N Engl J Med, 380, pp.1235~1246 (2019)
67. de Morree ES, "Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered : a post hoc analysis of the mainsail study", JAMA Oncol, 3, pp.68~75 (2017)
68. de Bono JS, "Subsequent chemotherapy and treatment patterns after abiraterone acetate in patients with metastatic castration-resistant prostate cancer : post hoc analysis of COU-AA-302", Eur Urol, 71, pp.656~664 (2017)
69. Khalaf DJ, "Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer : a multicentre, randomised, open-label, phase 2, crossover trial", Lancet Oncol, 20, pp.1730~1739 (2019)
70. Lavaud P, "Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-naive prostate cancer in the GETUG-AFU 15 phase 3 trial", Eur Urol, 73, pp.696~703 (2018)
71. Mountzios I, "Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer", Urology, 77, pp.682~687 (2011)
72. Caffo O, "Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel : assessment of clinical outcomes and predictive factors", Urology, 79, pp.644~649 (2012)
73. Di Lorenzo G, "Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer", BJU Int, 107, pp.234~239 (2011)
74. Scher HI, "Prostate cancer clinical trial end points : "RECIST"ing a step backwards", Clin Cancer Res, 11, pp.5223~5232 (2005)
75. Saad F, "A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma", J Natl Cancer Inst, 94, pp.1458~1468 (2002)
76. Saad F, "Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer", J Natl Cancer Inst, 96, pp.879~882 (2004)
77. Small EJ, "Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer", J Clin Oncol, 21, pp.4277~4284 (2003)
78. Ernst DS, "Randomized, double-blind, controlled trial of mitoxantrone", prednisone and clodronate versus mitoxantrone, J Clin Oncol, pp.2003, 21[DOI]
79. Fizazi K, "Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer : a randomised, double-blind study", Lancet, 377, pp.813~822 (2011)
80. Smith MR, "Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases : results of CALGB 90202(alliance)", J Clin Oncol, 32, pp.1143~1150 (2014)
81. Kamba T, "A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease : results of the ZAPCA trial", Int J Clin Oncol, 22, pp.166~173 (2017)
82. Droz JP, "Management of prostate cancer in older patients : updated recommendations of a working group of the International Society of Geriatric Oncology", Lancet Oncol, 15, pp.e404~e414 (2014)
83. Horwich A, "Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 24(Suppl 6), pp.vi106~vi114 (2013)
84. Body JJ, "Hypocalcaemia in patients with metastatic bone disease treated with denosumab", Eur J Cancer, 51, pp.1812~1821 (2015)
85. Bienz M, "Androgen-deprivation therapy and bone loss in prostate cancer patients : a clinical review", Bonekey Rep, 4, pp.716~ (2015)
86. Smith MR, "Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer", J Urol, 175, pp.136~139 (2006)
87. Shahinian VB, "Risk of fracture after androgen deprivation for prostate cancer", N Engl J Med, 352, pp.154~164 (2005)
88. Michaelson MD, "Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer", J Clin Oncol, 25, pp.1038~1042 (2007)
89. Greenspan SL, "Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer : a randomized trial", Ann Intern Med, 146, pp.416~424 (2007)
90. Smith MR, "Denosumab in men receiving androgen-deprivation therapy for prostate cancer", N Engl J Med, 361, pp.745~755 (2009)
91. Lutz S, "The role of radiation therapy in controlling painful bone metastases", Curr Pain Headache Rep, 16, pp.300~306 (2012)
92. Goblirsch MJ, "Biology of bone cancer pain", Clin Cancer Res, 12, pp.6231s~6235s (2006)
93. Vakaet LA, "Pain control by ionizing radiation of bone metastasis", Int J Dev Biol, 48, pp.599~606 (2004)
94. Hartsell WF, "Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases", J Natl Cancer Inst, 97, pp.798~804 (2005)
95. Chow E, "Single versus multiple fractions of repeat radiation for painful bone metastases : a randomised, controlled, non-inferiority trial", Lancet Oncol, 15, pp.164~171 (2014)
96. Chow E, "Update on the systematic review of palliative radiotherapy trials for bone metastases", Clin Oncol(R Coll Radiol), 24, pp.112~124 (2012)
97. Huisman M, "Effectiveness of reirradiation for painful bone metastases : a systematic review and meta-analysis", Int J Radiat Oncol Biol Phys, 84, pp.8~14 (2012)
98. Holzbeierlein JM, "Complications of androgen deprivation therapy for prostate cancer", Curr Opin Urol, 14, pp.177~183 (2004)
99. Elliott S, "Androgen deprivation therapy for prostate cancer : recommendations to improve patient and partner quality of life", J Sex Med, 7, pp.2996~3010 (2010)
100. de Voogt HJ, "Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer : results from European Organization for Research on Treatment of Cancer trials 30761 and 30762", J Urol, 135, pp.303~307 (1986)
101. Tunio MA, "Optimal prophylactic and definitive therapy for bicalutamide-induced gynecomastia : results of a meta-analysis", Curr Oncol, 19, pp.e280~e288 (2012)
102. Viani GA, "Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?", Int J Radiat Oncol Biol Phys, 83, pp.e519~e524 (2012)
103. Lu-Yao G, "Changing patterns in competing causes of death in men with prostate cancer : a population based study", J Urol, 171, pp.2285~2290 (2004)
104. O’Farrell S, "Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer", J Clin Oncol, 33, pp.1243~1251 (2015)
105. Saigal CS, "Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer", Cancer, 110, pp.1493~1500 (2007)
106. Bosco C, "Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer : a meta-analysis", Eur Urol, 68, pp.386~396 (2015)
107. Keating NL, "Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer", J Clin Oncol, 24, pp.4448~4456 (2006)
108. D’Amico AV, "Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions", J Clin Oncol, 25, pp.2420~2425 (2007)
109. Efstathiou JA, "Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer : RTOG 85-31", J Clin Oncol, 27, pp.92~99 (2009)
110. Nguyen PL, "Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer : a meta-analysis of randomized trials", JAMA, 306, pp.2359~2366 (2011)
111. Roach M 3rd, "Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer : longterm results of RTOG 8610", J Clin Oncol, 26, pp.585~591 (2008)
112. Tsai HK, "Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality", J Natl Cancer Inst, 99, pp.1516~1524 (2007)
113. Voog JC, "Cardiovascular mortality following short-term androgen deprivation in clinically localized prostate cancer : an analysis of RTOG 94-08", Eur Urol, 69, pp.204~210 (2016)
114. Wilcox C, "Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term", Oncology, 82, pp.56~58 (2012)
115. D’Amico AV, "Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer", JAMA, 314, pp.1291~1293 (2015)
116. Levine GN, "Androgen-deprivation therapy in prostate cancer and cardiovascular risk : a science advisory from the American Heart Association, American Cancer Society, and American Urological Association : endorsed by the American Society for Radiation Oncology", Circulation, 121, pp.833~840 (2010)
117. Guan J, "Cardiology patient page : ABCDE steps for heart and vascular wellness following a prostate cancer diagnosis", Circulation, 132, pp.e218~e220 (2015)
118. Shahinian VB, "Risk of the"androgen deprivation syndrome"in men receiving androgen deprivation for prostate cancer", Arch Intern Med, 166, pp.465~471 (2006)
119. Nead KT, "Association between androgen deprivation therapy and risk of dementia", JAMA Oncol, 3, pp.49~55 (2017)
120. Alibhai SM, "Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer", J Clin Oncol, 28, pp.5030~5037 (2010)
121. Cherrier MM, "Testosterone supplementation improves spatial and verbal memory in healthy older men", Neurology, 57, pp.80~88 (2001)
122. Green HJ, "Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate : a randomized controlled trial", BJU Int, 90, pp.427~432 (2002)
123. Sun M, "Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy : a systematic review and meta-analysis", J Urol, 199, pp.1417~1425 (2018)
124. Yang J, "Dissociation of event-based prospective memory and time-based prospective memory in patients with prostate cancer receiving androgen-deprivation therapy: a neuropsychological study", Eur J Cancer Care(Engl), 24, pp.198~204 (2015)
125. Hirano D, "Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy", Eur Urol, 45, pp.586~592 (2004)
126. Ismail A HR, "Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate", Prostate, 51, pp.117~125 (2002)
127. Nadal R, "Small cell carcinoma of the prostate", Nat Rev Urol, 11, pp.213~219 (2014)
128. Wang HT, "Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis", J Clin Oncol, 32, pp.3383~3390 (2014)
129. Aggarwal R, "Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer : a multi-institutional prospective study", J Clin Oncol, 36, pp.2492~2503 (2018)
130. Yao JL, "Small cell carcinoma of the prostate : an immunohistochemical study", Am J Surg Pathol, 30, pp.705~712 (2006)
131. Spiess PE, "Treatment outcomes of small cell carcinoma of the prostate : a single-center study", Cancer, 110, pp.1729~1737 (2007)
132. Corn PG, "Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers : a randomised, open-label, phase 1-2 trial", Lancet Oncol, 20, pp.1432~1443 (2019)

관련 논문AI추천